Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) has completed its initial public offering (IPO) on NASDAQ, raising US $201 million through the issuance of 10.6 million shares at US $19 per share.
Black Diamond Therapeutics was the first company to emerge from Ridgeline, Versant Ventures’ Discovery Engine based in the Basel Technology Park.
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. The company’s proprietary technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.
Founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and, funded with US $20 million Series A from Versant, Black Diamond began building the MAP platform and chemistry discovery engine in 2017.
Black Diamond Therapeutics raised more than US $194 million in funding from Versant Ventures, New Enterprise Associates, RA Capital Management, Boxer Capital, LLC, Tavistock Group, NexTech Invest, The Invus Group, Perceptive Advisors, Wellington Management, BVF Partners L.P., Deerfield Management, Janus Henderson Investors, Casdin Capital, Logos Capital, City Hill Ventures, and Roche Venture Fund.
Following the closing of the IPO, Versant Ventures, New Enterprise Associates, RA Capital Management, Boxer Capital will continue to control 47.7% of outstanding shares.
Headquartered in Cambridge, Massachusetts, Black Diamond Therapeutics also maintains lab and office spaces in New York City and Toronto.
With offices in the U.S., Canada and Europe, Versant is currently investing out of its seventh fund, Versant Venture Capital VII, a US $600 million global biotech fund closed in December 2018. In parallel the firm co-invests out of its Canadian strategic fund Versant Voyageurs I and its later-stage biotech opportunity fund Versant Vantage I.
photo credit: Black Diamond Therapeutics
Versant Ventures Announces Successful IPO by Black Diamond Therapeutics
— First company launched by Versant’s Ridgeline Discovery Engine —
January 29, 2020 11:00 PM Eastern Standard Time
SAN FRANCISCO & BASEL, Switzerland–(BUSINESS WIRE)–Versant Ventures today announced that Black Diamond Therapeutics completed an IPO on NASDAQ, raising $201 million through the sale of 10.6 million shares at $19. Black Diamond (NASDAQ: BDTX) was the first company to emerge from Ridgeline, Versant’s Discovery Engine based in the Basel Technology Park.
Ridgeline’s research laboratories were established during March 2017 with a team of accomplished discovery scientists from leading pharmaceutical companies including Roche and Novartis. The mission was to enable entrepreneurs to more effectively launch and progress Versant-backed start-ups.
Black Diamond debuted in December 2018 with a $20 million Series A financing exclusively from Versant. The Ridgeline team collaborated with company founders on the MAP (Mutation-Allostery-Pharmacology) platform to uncover, discover and target allosteric mutant oncogenes. This involved translational work to create chemical leads, validate the resulting targets and bring forward drug candidates.
Subsequently, Black Diamond raised nearly $200 million from follow-on private financings to further develop the MAP platform and generate a pipeline of orally available potent and selective small molecule kinase inhibitors that target a range of driver mutations. The company’s first two disclosed programs are targeting groups of EGFR and HER2 allosteric mutants. The most advanced product candidate, BDTX-189, is expected to start a combined Phase 1/2 clinical trial in the first half of 2020.
About Versant Ventures
Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $3.2 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 75 Versant companies have achieved successful acquisitions or IPOs. Versant is currently investing out of its seventh fund, Versant Venture Capital VII, a $600 million global biotech fund closed in December 2018. In parallel the firm co-invests out of its Canadian strategic fund Versant Voyageurs I and its later-stage biotech opportunity fund Versant Vantage I. For more information, please visit www.versantventures.com.
Steve Edelson, senior director of communications and investor relations